Introduction
Inflammatory breast carcinoma (IBC) is an aggressive form of human breast cancer characterized by florid lymphovascular invasion (LVI) and early metastasis (Palangie et al., 1994; Cariati et al., 2005) . LVI is considered a rate-limiting step in the metastatic process and is characterized by tumor emboli within lymphovascular channels. These emboli are resistant to radiotherapy and chemotherapy (Alpaugh and Barsky, 2002; Alpaugh et al., 2002a, b; Xiao et al., 2008) . The IBC phenotype has been successfully recapitulated in a human xenograft model of IBC termed MARY-X (Tomlinson et al., 2001) . This model exhibits florid LVI in vivo, which generates tight tumor cell aggregates (spheroids) in vitro. These spheroids resemble the human blastocyst. Both structures overexpress E-cadherin, and have a deficiency of fucosyltransferases and surface fucosylation (Alpaugh et al., 2002b) , but are efficient at organ implantation. On account of these similarities, we wondered whether the spheroids might express a blastocyst-like expression profile. Based on microarray data, we observed that certain embryonic pathways, like Notch 3, appeared activated and so we decided to investigate this further.
Results

MARY-X exhibits a 'blastocyst-like' phenotype with exaggerated Notch 3 signaling
The MARY-X xenograft gave rise to tight spheroids in suspension culture. When re-injected into immunodeficient mice, these spheroids manifested lymphovascular emboli within dermal lymphatics. Screening of the spheroids by expression profiling revealed increased Notch, specifically Notch 3. The downstream genes, HES-5 and HEY-2, were noted by expression profiling also to be overexpressed (Po0.0001), suggesting the possibility of Notch signaling. More detailed reverse transcriptase (RT)-PCR, real-time RT-PCR, western blot and immunocytochemical studies looking at Notch 3 (Xiao et al., 2008) and expanding the number of Notch targets confirmed these findings .
Although other Notch receptors were expressed in some of the non-IBC and normal lines, Notch 3 dominated in MARY-X (Figure 1a) , even when the non-IBC carcinoma and normal lines were induced to grow as spheroids. MARY-X spheroids expressed the highest levels of six different Notch target genes: HES-5, HEY-1, c-Myc, Deltex-1, NRARP and PBX1, among all tested breast cancer cell lines (Figures 1b and d) . Actually, in nine Notch target genes (including HES-1, HEY-2 and GATA3), MARY-X exhibited significantly higher expression levels than MDA-MB-468 and MDA- (Sternlicht et al., 1996; Barsky, 2003) , it was the dominant expression of Notch 3 that stood out in MARY-X. (b) Notch targets HEY-2 and HES-5, detected by RT-PCR, were prominent in MARY-X and MARY-X spheroids. (c) Evidence of Notch 3 signaling was also seen in the MARY-X xenograft by the presence of N3icd nuclear immunoreactivity (upper panel), and downstream HES-5 nuclear immunoreactivity (middle panel) compared with IgG control (lower panel). (d) Relative expression levels by real-time RT-PCR of select downstream targets of Notch, c-Myc, Deltex-1, NRARP and PBX1 in MARY-X compared with other breast carcinoma lines. All were significantly increased in MARY-X. (e) Relative expression levels by real-time RT-PCR of another downstream target of Notch, GATA3, which was expressed at higher levels in MCF-7 than MARY-X. Still, MARY-X expressed higher levels of GATA3 than the estrogen receptor-negative lines. (f) Cellular compartmentalization of N3icd and N1icd. In MARY-X spheroids, N3icd was located predominately in the nuclear compartment, whereas N1icd was located mainly in the membrane. The former normally signaled and the latter did not. When the cells were treated with g-secretase inhibitors (GSI treatment), the N3icd remained confined to the membrane, which is evidence of inhibition of Notch 3 signaling. As Notch 1 levels were low to begin with, with no appreciable signaling, its cellular compartmentalization was unaffected by GSI treatment. DMSO, dimethylsulfoxide.
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Y Xiao et al d and e) , but MCF-7 showed higher level of HES-1 and GATA3 expression than MARY-X. MCF-7, in fact, exhibited much higher (417-fold) expression levels of GATA3 than MARY-X. Notch 3 signaling manifested itself not only in the MARY-X spheroids but also in the MARY-X xenograft. In the latter settings, prominent nuclear Notch 3 intracellular domain (N3icd) and HES-5 immunoreactivities were present, which was evidence that the Notch 3 receptor had been cleaved, translocated to the nucleus and engaged in downstream signaling ( Figure 1c ). MARY-X spheroids also exhibited a loss of Numb expression (data not shown). The anti-N3icd antibody used, which recognized the cleaved intracellular domain of Notch 3, demonstrated strong nuclear and cytoplasmic cellular compartmentalization (Figure 1f ). In contrast, anti-Notch 1 intracellular domain (N1icd) antibody demonstrated only weak membrane compartmentalization. Other Notch members (Notch 2, Notch 4) exhibited no nuclear immunoreactivity in the MARY-X spheroids (data not shown).
As many of the non-IBC lines expressed Notch receptors but did not demonstrate robust Notch signaling (Figures 1b and d) , we investigated possible reasons for the selective Notch 3 dominance in MARY-X. The entire Notch 1-4 receptors were sequenced in MARY-X and found to be normal. Specifically there were no mutations or deletions. Although array comparative genomic hybridization revealed a moderately amplified Notch 2 locus (1p13-11), the Notch 3 locus was not amplified. We did note, however, that Jagged-1 and DLL1 in MARY-X were slightly increased. However, knockdown of Jagged-1 with small interfering RNA (siRNA) had no effect on the MARY-X spheroids (data not shown) compared with the pronounced effect of Notch 3 knockdown on apoptosis (see the next section). Knockdown of DLL1 was attempted but could not be technically achieved.
Directly inhibiting Notch 3 signaling in MARY-X spheroids induces apoptosis We sought to inhibit Notch signaling by two different experimental manipulations: inhibition of its enzymatic cleavage ( Figure 2 ) and Notch 3 knockdown with siRNA ( Figure 3 ). Notch signaling is thought to be dependent on two proteolytic cleavage events in the Notch receptor, an initial extracellular domain cleavage by the ADAM metallopeptidase domain 10, which is thought to be triggered by ligand binding, and a subsequent intramembranous cleavage by g-secretase, which releases the Nicd to the nucleus, where it activates a number of downstream genes, including the HES and HEY family of basic helix-loop-helix transcriptional repressors.
We then sought to initially inhibit Notch signaling by directly targeting the g-secretase with g-secretase inhibitors (GSIs; Figure 2 ). As the actions of g-secretase and g-secretase inhibition were not specific for Notch 3, we subsequently targeted Notch 3 with an siRNA knockdown approach as well (Figure 3 ).
Initially we screened a series of secretase inhibitors ( Table 1 ), peptides that mimicked the binding structure of the amyloid precursor protein (APP) and peptides that are able to inhibit APP processing, for their ability to inhibit Notch cleavage and nuclear translocation. Both b-secretase inhibitors and GSIs were initially screened with immunohistochemistry studies for their ability to inhibit N3icd nuclear translocation over a range of concentrations. We used both classes of secretase inhibitors initially, even though b-secretase is not thought to be involved in the cleavage of Notch, to provide a negative control for g-secretase cleavage. The GSIs, specifically a particular GSI-I (Z-Leu-Leu-Nle-CHO), were the more potent (Table 1 ). In as little as 4 h and with as low a concentration as 0.8 mM, GSI-I totally abolished N3icd nuclear immunoreactivity and kept the Notch 3 immunoreactivity confined to the plasma membrane of the MARY-X spheroids ( Figure 2a ). The inhibition of Notch 3 signaling was also manifested by dramatic decrease in the expression levels of the downstream genes HES-5 and HEY-2, measured by RT-PCR ( Figure 2b ). The inhibition of the downstream genes began as early as 2 h and peaked at 10 h following GSI-I treatment. Activated caspase 3 was noted as early as 8 h following treatment and peaked at 24 h (Figure 2c ). Endonuclease-mediated nucleosome excision manifesting as a DNA apoptosis ladder was also noted at 8 h and peaked at 24 h ( Figure 2d ). As the inhibitory actions of the GSIs may not have been limited to only g-secretases, especially considering recent studies that revealed that the aldehyde group on the GSI-I peptide was able to covalently bind to and inhibit certain serine proteases (Curry et al., 2005) , we had to exclude the possibility that the results we observed on the inhibition of Notch signaling were due to the inhibition of serine proteases and not g-secretases. To accomplish this, we performed experiments with GSI XIX, a noncovalent peptidomimetic inhibitor of g-secretases that is not able to bind serine proteases. Similar results on notch cleavage (Table 1) , upregulation of activated caspase 3 and apoptosis were observed with this inhibitor as were observed with GSI-I (data not shown). As g-secretases may cleave not only Notch but also ErbB4, syndecan and other substrates (Shih and Wang, 2007) , we had to also exclude the possibility that these other g-secretase substrates might be mediating the apoptosis response when g-secretase was inhibited.
To do this, we attempted to specifically inhibit Notch signaling by knockdown of the Notch receptor itself using a siRNA approach. More than 90% knockdown of both mRNA as measured by real-time PCR (Figure 3a ) as well as protein as measured by western blot (Figure 3b ) was achieved. Both control NCSI as well as luciferase siRNA had no effect.
The effects of Notch 3 knockdown with siRNA were virtually identical to the effects with GSI-I: inhibition of the Notch downstream genes, HEY-2 and HES-5, activation of caspase 3 and a DNA ladder of apoptosis (data not shown). Notch 1 and Jagged-1 knockdown were effective at achieving specific knockdown of their respective targets, but they did not have any effects on Notch downstream signaling or the induction of apoptosis (data not shown).
With both the g-secretase inhibition and Notch 3 interference, morphological changes within the spheroids became noticeable within 12-24 h (Figure 3c ). These morphological changes suggested that apoptosis was occurring initially around the periphery of the spheroids. In the setting of both g-secretase inhibition and Notch 3 interference, apoptosis preceded the disadherence.
Inhibiting Notch 3 signaling in the MARY-X xenograft has similar but diffusion-limited effects We extended these Notch signaling inhibition experiments in vivo to the MARY-X xenografts. Use of GSI-I Notch 3 dependency of IBC embolus Y Xiao et al in vivo resulted in similar inhibiting effects on Notch signaling, caspase 3 activation and apoptosis (Figure 2e ), resulting in a reduction in the growth rate of the xenografts but not frank tumor regression ( Figure 2f ). These effects were more pronounced near the injection site of the drug and became less pronounced further away from the injection site, suggesting diffusion-limiting effects.
MARY-X spheroids exhibit high aldehyde dehydrogenase (ALDH) activity, which in turn exhibits concordance with Notch 3 signaling A high activity of ALDH, a marker for both normal and cancer stem cells, was observed in the cells comprising the MARY-X spheroids. When the spheroids were disadhered into single cells, approximately 23% of the cells exhibited ALDH activity by the ALDEFLUOR (Figure 4a ). In contrast, the non-IBC lines and normal mammary epithelial cells exhibited very low percentages (1-5%) of ALDH activity (data not shown). We then investigated the secondary spheroidgenesis and tumorigenicity capacities of the sorted ALDH þ subpopulation. Our studies indicated that (1) only ALDH þ cells were capable of forming both secondary spheroids as well as tumors (Table 2 ) and (2) ALDH þ cells were able to give rise to both ALDH þ and ALDH À cells, that is, a heterogeneous cell population ( Figure 4a ). These results suggested that ALDH þ cells in the MARY-X spheroids exhibited a stem cell-like phenotype.
The presence of ALDH activity was corroborated by the presence of similar levels of ALDH1 immunoreactivity within the lymphovascular emboli of MARY-X, which also exhibited concordant N3icd immunoreactivity by dual colorimetric immunocytochemical methods (Figure 4b ). The MARY-X spheroids also demonstrated increased Notch 3 signaling, by real-time RT-PCR, of HES-5 and HEY-2 compared with the levels exhibited by non-IBC lines and normal mammary epithelial cells (Figure 4c ). When the single cells of MARY-X were sorted on the basis of ALDH þ , Notch 3 signaling was further enhanced (Figure 4c ).
Transfection of N3icd into human mammary epithelial cells (HMEC) induces Notch signaling
To examine this Notch 3 signaling further but from a different perspective, we conducted a set of 'reverse' experiments: transfection of N3icd into HMEC that normally lack Notch 3 signaling, CD133 expression and a Notch 3 addiction. Introduction of N3icd into HMEC achieved a level of Notch 3 signaling equal to that in MARY-X (Figure 5a ). N3icd but not N1icd induced in HMEC CD133 expression (Figures 5b and c) and numerous other notch targets (Figure 5d ) and morphological changes reflecting spheroidgenesis (anchorageindependent growth) ( Figure 5e ). Inhibition of notch signaling by g-secretase inhibition or Notch 3 interference in the MARY-X spheroids decreased CD133 (Figure 5f ) and abolished spheroidgenesis.
Gene expression profiles of MARY-X spheroids share common overexpressions with CD44 þ immunosorted cells and CD44
þ mammospheres/neurospheres The gene expression profiles of each of these acknowledged models of mammary gland stem cells revealed many genes in common that were overexpressed (Table 3) . Specifically there were a total of 766 genes overexpressed in the MARY-X spheroids compared with MDA-MB-231, MDA-MB-468 and HMEC (Po0.001). There were a total of 291 genes overexpressed in CD44
þ human breast cancer cells compared with CD24
þ breast cancer cells (Po0.01). There were a total of 102 genes overexpressed in both the human mammospheres and neurospheres (Po0.01). We identified 36 overexpressed genes in common between the MARY-X spheroids and CD44
þ breast cancer cells. There were 12 overexpressed genes in common among MARY-X spheroids and the human mammospheres and neurospheres. We found three overexpressed genes, C1R, CHI3L1 and Notch 3, in common in all three groups.
Observations made in MARY-X are applicable to human cases of IBC of all molecular subclasses To test whether the MARY-X observations were applicable to actual human cases of IBC, we conducted Notch 3 and ALDH1 colocalization immunohistochemistry studies of 25 cases of IBC, 25 cases of non-IBC and 5 normal breast tissues, of which frozen tissues had been collected in the past and banked anonymously. In the IBC cases, we also looked for evidence of Notch 3 downstream signaling by HES-5 and HEY-2 immunoreactivities. The distribution of the IBC and the non-IBC subtypes is depicted in Table 4 . Out of 25 IBC cases, 20 (80%) expressed Notch 3 nuclear immunoreactivity and 23 (92%) expressed ALDH1 cytoplasmic immunoreactivity; there were no significant differences among the subclasses of IBC for expression of either stem cell marker (Table 4 ). The IBC cases with positive N3icd nuclear immunoreactivity failed to show equivalent N1icd or N4icd nuclear immunoreactivities (Figure 6 ). Non-IBC cases, except for triple negative, were largely negative for N3icd nuclear immunoreactivity and exhibited a lower overall percentage of cytoplasmic ALDH1 positivity. The expression of N3icd and ALDH1 in the cases overall was highly concordant (weighted Kappa (95% confidence interval) ¼ 0.76 (0.71, 0.81)) ( Table 4) .
Discussion
Recent experimental evidence has supported the concept of cancer stem cells that retain the embryonal cell 
The effects of each of these inhibitors on Notch3 signaling (nuclear translocation) were measured immunocytochemically on a semi-quantitative ordinal scale and scored subjectively.
Notch 3 dependency of IBC embolus Y Xiao et al properties of self-renewal and developmental potential (Bonnet and Dick, 1997; Rachel et al., 2001; Reya et al., 2001; Kubota et al., 2003; Clark et al., 2004; Sheila et al., 2004; Laurie et al., 2005; Wicha et al., 2006) . Notch signaling is an example of a highly conserved pathway that is involved in multiple fundamental processes in both embryogenesis and oncogenesis (AndroutsellisTheotokis et al., 2006; Bray, 2006; Chiba, 2006) . MARY-X grows as tight spheroids, whereas the cell lines (breast cancer, and normal epithelial and myoepithelial) to which it is compared normally grow as monolayers. The differences observed with respect to , 2005) , and has also been seen in animal models (Gallahan and Callahan, 1997; Dievart et al., 1999; Callahan and Egan, 2004; Hu et al., 2006) . Overexpression of active forms of murine Notch 1-4 The gene expression profile of CD44 þ immunosorted cells was obtained from a published study (Shipitsin et al., 2007) . The gene expression profile of CD44 þ mammospheres/neurospheres was obtained from a published study (Dontu et al., 2003) .
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inhibited mammary differentiation and caused tumors in transgenic mice (Dievart et al., 1999) . However, with human Notch, the story has become more complicated. Notch, especially Notch 1, has been shown to signal in a number of different human breast cancer cell lines and to induce EMT through slug-mediated repression of E-cadherin (Stylianou et al., 2006; Leong et al., 2007) . Some studies have revealed, however, that Notch was not sufficient for transformation when it was activated alone (Ayyanan et al., 2006) but needed to synergize with additional molecular alterations to promote neoplastic transformation (Leong and Karsan, 2006) . The cross-talk between Notch and other oncogenetic signaling pathways could then form a feed-forward loop that promoted tumor cell growth (Girard et al., 1996; Palomero et al., 2006) . The overall pattern of Notch expression and its downstream genes is indeed complicated. Clearly, other non-IBC and ductal carcinoma in situ cell lines express Notch family members (Farnie et al., 2007) . The MDA-MB-231 line expresses Notch 1 and Notch 4. The MDA-MB-468 line expresses Notch 1 (Stylianou et al., 2006) and Notch 3 (Yamaguchi et al., 2008) . The MCF-7 line expresses Notch 1 (Stylianou et al., 2006; Rizzo et al., 2008) , Notch 3 (Yamaguchi et al., 2008) and Notch 4 (Sun et al., 2005) . However, Notch 3 selectively dominates in MARY-X.
MARY-X also demonstrated a much greater activation of downstream Notch target genes than the other non-IBC lines. These target genes included HES-5, HEY-1, c-Myc, Deltex-1, NRARP and PBX1. The lastmentioned Notch target, PBX1, was recently identified as a specific Notch 3 target gene in ovarian cancer (Park et al., 2008) . But MCF-7 showed higher levels of HES-1 and GATA3 expression than MARY-X. Clearly, not every Notch target has to be increased in MARY-X to argue that overall MARY-X exhibits increased Notch 3 signaling. In fact, it has been argued that the cell type (91) 5 (83) 23 (92) 3 (60) 1 (17) 2 (14) 6 ( Studies revealed the presence of significant nuclear immunoreactivities for Notch 3 but not Notch 1 or Notch 4, independent of molecular subtype. Triple-negative IBC (a) exhibited strong N3icd nuclear immunoreactivity (b), but weak-to-absent nuclear N1icd (c) and N4icd (d) immunoreactivities. Her-2/neu-positive IBC (e) similarly exhibited strong N3icd nuclear immunoreactivity (f), but weak-to-absent nuclear N1icd (g) and N4icd (h) immunoreactivities. Even ER-positive IBC (i) exhibited strong N3icd nuclear immunoreactivity (j) but weak-to-absent nuclear N1icd (k) and N4icd (l) immunoreactivities.
and specific tumoral microenvironment may influence which specific Notch target genes are induced by Notch signaling (Iso et al., 2003) . The expression levels of the downstream Notch targets are probably a better indication of Notch signaling than Notch levels per se. The literature also suggests that Notch 3 exhibits features distinct from other Notch family receptor members. For example, Notch 3 contains a specialized TAD domain in the C-terminal region, which would be expected to preferentially activate promoters with zinc-finger binding sites near a CSL-binding site, such as contained within the HES-5 promoter (Bellavia et al., 2008) . As one might predict from this, MARY-X exhibited the highest level of HES-5 (148-fold greater than all other breast carcinoma cell lines tested). Furthermore, not all Notch targets are specific for Notch. For example, HEY-1 can be a downstream target of transforming growth factor beta as well.
The mechanisms of increased Notch 3 signaling in MARY-X remain unknown. Some studies have suggested that in some cancers increased Notch gene copy number can correlate with increased Notch signaling (Bray, 2006; Leong and Karsan, 2006; Park et al., 2006) . In our study, although we noted that the Notch 2 locus (1p13-11) in Mary-X was moderately amplified on array comparative genomic hybridization, the Notch 3 locus was not amplified. It had also been demonstrated that mutations within Notch receptors can activate signaling in the absence of a ligand (Sanchez-Irizarry et al., 2004; Weng et al., 2004; Gordon et al., 2007) . However, we did not find these gain-of-function mutations in Notch 3 in Mary-X. Although the loss of Numb is thought to enable Notch signaling, the loss of Numb in MARY-X does not fully explain Notch 3 activation. As Notch signaling begins with ligand binding, it was reasonable for us to hypothesize that Notch activation in MARY-X is triggered by the close juxtaposition of ligand with receptors on neighboring cells within the tight spheroid aggregate. We did observe reasonable levels of expression of the Notch ligand, Jagged-1, in the intact MARY-X spheroids. However, Jagged-1 knockdown with siRNA did not decrease Notch 3 signaling and DLL1 knockdown could not be technically achieved. These findings all show that the mechanism of Notch 3 activation in MARY-X spheroids is still a mystery.
Another hypothesis we can consider to explain why the MARY-X spheroids exhibit Notch 3 rather than Notch 1 activation is that these spheroids are deficient in fucosyl transferases (Alpaugh et al., 2002a, b) . Fucosyl transferases, specifically Pofut-1, are required for the processing of Drosophila Notch and mammalian Notch 1 (Kopan and LLagan, 2009) . One possibility then is that the MARY-X cells cannot adequately process Notch 1, leading to a relative loss of Notch 1 signaling and a compensatory increase in Notch 3 activity.
As the effects of g-secretase inhibition were neither Notch 3 specific nor even g-secretase specific, we decided to carry out specific Notch 3 knockdown experiments. The effects of Notch 3 knockdown were identical to the effects of g-secretase inhibition in vitro, namely decreased expression of Notch 3 targets and profound apoptosis. It had been shown previously that Notch signaling can regulate apoptosis (Jhappan et al., 1992; Hu et al., 2006; Klinakis et al., 2006) . Results of our in vitro studies were cleaner than our in vivo results that relied on the diffusion of a drug, in this case, GSI-I. Intratumor injection studies generally are imprecise and messy. We have attempted to lentivirally transfect in vitro both a short hairpin RNA Notch 3 construct as well as a DNAmastermind construct in MARY-X spheroids and see the effects of these maneuvers on the growing xenograft. DNAmastermind is an inhibitor of notch signaling (Giraldez et al., 2002) . However, emerging clones with either transfection did not exhibit sustained growth in vitro and could not be used for an in vivo study. We are contemplating the use of a conditional knockdown system like cre/lox so that the effects of Notch 3 short hairpin RNA or DNA mastermind can be studied in vivo.
Our MARY-X model exhibited relatively high expression of ALDH enzymatically and ALDH1 immunocytochemically. ALDH1 has been shown to be a marker for normal and malignant human mammary stem cells and a predictor of poor clinical outcome in human breast cancer (Ginestier et al., 2007) . The sorted ALDH þ subpopulation of MARY-X exhibited enriched Notch 3 downstream signaling, increased spheroidgenesis and tumorigenicity (Table 2) . Interestingly, colocalization of Notch 3 and ALDH1 immunoreactivities could be demonstrated within the lymphovascular emboli of MARY-X.
The gene expression profile of the MARY-X spheroids was compared with the published gene expression profile of acknowledged models of mammary gland stem cells: CD44 þ mammospheres/neurospheres and CD44 þ immunosorted cells (Dontu et al., 2003; Shipitsin et al., 2007) . Several genes in common, including Notch 3 (Sansone et al., 2007a, b) , were overexpressed in all three models (Table 3) . One gene that was overexpressed only in the MARY-X spheroids was Il-6. It is interesting to postulate that interleukin-6 may be responsible for the clinical findings of IBC: a reddened, swollen and tender breast in the absence of inflammatory cells.
It is important to verify that the insights gained by studying Notch 3 signaling and ALDH1 positivity in MARY-X are applicable to human IBC. It could be argued, however, that the stem cell-like properties of Notch 3 signaling and ALDH positivity exhibited by MARY-X (as it is triple negative) could be a manifestation of its basal origin rather than its IBC origin (Bertucci et al., 2006; Stylianou et al., 2006; Yamaguchi et al., 2008; Sansone et al., 2007a, b) . IBC is a heterogeneous disease and it has been reported that the same molecular subtypes present in non-IBC are also present in IBC (Bertucci et al., 2005) . The stem cell markers observed in MARY-X, namely Notch 3 and ALDH1, were not limited to triple-negative IBC, but were observed in ER-positive and Her-2/neu-positive IBC as well. The IBC stem cell-like phenotype transcended all the molecular subtypes of IBC.
The MARY-X spheroids, in particular, and IBC, in general, resist chemotherapy and radiation-induced apoptosis. The mechanisms underlying this resistance to apoptosis remain unknown. However, the present observations would suggest that the presence of Notch signaling in the intact spheroid might be one mechanism.
The therapeutic efficacy of notch inhibitors has been observed in other human cancer cell lines (Haruki et al., 2005; Park et al., 2006) . Although pharmacological therapy with GSI-I was very effective in vitro, it was less effective in vivo, probably because of diffusion-limited effects of either tissue solubility or half-life. These limitations might be circumvented by designing a more polar GSI. Notch has certainly become an attractive target for anti-cancer drug development (Leong and Karsan, 2006; Shih and Wang, 2007) . In IBC we have demonstrated the addiction of the lymphovascular embolus to Notch 3 activation and suggest that targeting that pathway might provide a therapeutic advantage. Cell lines and xenograft studies MARY-X, established from an IBC patient, exhibited florid LVI with tumor emboli formation in nude/severe combined immunodeficiency mice (Alpaugh et al., 1999; Tomlinson et al., 2001; Alpaugh and Barsky, 2002 ) (see Supplementary Information).
Materials and methods
Institutional approvals and human tissues
Gene expression profile studies and array comparative genomic hybridization Details of these methods (Jain et al., 2002; Krzywinski et al., 2004) are provided in Supplementary Information.
RNA isolation, RT-PCR, real time PCR and sequencing studies Total RNA was isolated using RNeasy and treated with DNase (Qiagen, Valencia, CA, USA). Details of RNA isolation, PCR and sequencing studies are provided in Supplementary Information.
Immunocytochemical, immunoprecipitation, cell fractionation and western blot studies Details of these methods are provided in Supplementary Information.
Inhibition of Notch3 signaling in vitro and in vivo Inhibition of Notch 3 signaling in vitro and in vivo was performed on the MARY-X spheroids and xenograft using two approaches: RNA interference and secretase inhibition (see Supplementary Information).
Apoptosis measurements DNA was extracted from the MARY-X spheroids treated with GSI-I using the Suicide Track DNA Ladder isolation kit (Calbiochem Inc, San Diego, CA, USA). A terminal deoxynucleotidyl transferase dUTP nick end labeling assay was also performed (see Supplementary Information) .
ALDEFLUOR assay
The ALDEFLUOR kit (StemCell Technologies, Durham, NC, USA) was applied to identify a cell population with high ALDH enzymatic activity (see Supplementary Information).
N3icd transfection
To examine the effects of N3icd on cells that do not express Notch 3 signaling, N3icd was transfected into HMEC and the effects on target gene expression and morphogenesis was examined (see Supplementary Information).
Human IBC cases
In all, 25 cases of IBC were studied immunocytochemically for Notch 3, Notch 1, Notch 4 and ALDH1 (see Supplementary  Information) .
Statistical analysis
Standard tests of significance were used (see Supplementary  Information) .
